• Search
  • Advanced Search

Review

October 2, 2024


Roles of X-box binding protein 1 in liver pathogenesis
Jihoon Tak, Yun Seok Kim, Sang Geon Kim
Clin Mol Hepatol. 2025;31(1):1-31.

The prevalence of drug-induced liver injury (DILI) and viral liver infections presents significant challenges in modern healthcare and contributes to considerable morbidity and mortality worldwide. Concurrently, metabolic dysfunctionassociated steatotic liver...

Review

October 2, 2024


Sinusoidal communication in chronic liver disease
Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, et al.
Clin Mol Hepatol. 2025;31(1):32-55.

The liver sinusoid, mainly composed of liver sinusoidal endothelial cells, hepatic macrophages and hepatic stellate cells, shapes the hepatic vasculature and is key to maintaining liver homeostasis and function. During...

Review

October 21, 2024


Bioactive metabolites: A clue to the link between MASLD and CKD?
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, et al.
Clin Mol Hepatol. 2025;31(1):56-73.

Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the...

Review

October 23, 2024


Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, et al.
Clin Mol Hepatol. 2025;31(1):74-89.

One-third of adults across the globe exhibit metabolic dysfunction-associated steatotic liver disease (MASLD)―formerly known as nonalcoholic fatty liver disease (NAFLD). To date, MASLD is the fastest-growing etiology of chronic liver...

Review

November 11, 2024


Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
Atsumasa Komori, Yuki Kugiyama
Clin Mol Hepatol. 2025;31(1):90-104.

Patients with hard-to-treat autoimmune hepatitis (AIH) or primary biliary cholangitis (PBC) are defined a posteriori as those who do not show a sufficient response or are intolerant to pharmacological treatments,...

Original Article

July 11, 2024


Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
Chuan Liu, Hong You, Qing-Lei Zeng, et al.
Clin Mol Hepatol. 2025;31(1):105-118.

Backgrounds/Aims: Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol...

Original Article

September 24, 2024


Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial
Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, et al.
Clin Mol Hepatol. 2025;31(1):119-130.

Background/Aims: A clinical unmet need persists for medications capable of modulating the progression of primary sclerosing cholangitis (PSC). This study aimed to assess the clinical feasibility of HK-660S (beta-lapachone) in...

Original Article

October 2, 2024


Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, et al.
Clin Mol Hepatol. 2025;31(1):131-146.

Background/Aims: This study aimed to identify the risk factors for chronic kidney disease (CKD) and end-stage renal disease (ESRD) following liver transplantation (LT), with a specific focus on tacrolimus levels...

Original Article

October 2, 2024


USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu, Zhouxiang Wang, Kun Zhu, et al.
Clin Mol Hepatol. 2025;31(1):147-165.

Background/Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma,...

Original Article

October 4, 2024


Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, et al.
Clin Mol Hepatol. 2025;31(1):166-178.

Background/Aims: The World Health Organization (WHO) aims to eliminate hepatitis C virus (HCV) by 2030; therefore, widespread HCV screening is required. The WHO recommends HCV self-testing (HCVST) as a new...

Original Article

October 11, 2024


Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, et al.
Clin Mol Hepatol. 2025;31(1):179-195.

Background/Aims: Evidence suggests that the gastrointestinal microbiome plays a significant role in the biology of metabolic dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear whether disparities in the gut...

Original Article

October 15, 2024


Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma
Yang Liu, Fan Peng, Siyuan Wang, et al.
Clin Mol Hepatol. 2025;31(1):196-212.

Background/Aims: Early detection and effective prognosis prediction in patients with hepatocellular carcinoma (HCC) provide an avenue for survival improvement, yet more effective approaches are greatly needed. We sought to develop...

Original Article

October 17, 2024


Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial
Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Clin Mol Hepatol. 2025;31(1):213-226.

Background/Aims: Treatment indications for patients with chronic hepatitis B (CHB) remain contentious, particularly for patients with mild alanine aminotransferase (ALT) elevation. We aimed to evaluate treatment effects in this patient...

Original Article

November 14, 2024


Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, et al.
Clin Mol Hepatol. 2025;31(1):227-239.

Background/Aims: With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the...

Original Article

November 21, 2024


Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis
Anja Tiede, Lena Stockhoff, Zhaoli Liu, et al.
Clin Mol Hepatol. 2025;31(1):240-255.

Background/Aims: Systemic Inflammation (SI) is considered a key mechanism in disease progression and development of complications in decompensated liver cirrhosis. SI is mainly driven by portal hypertension and bacterial translocation....
Current Issue
Volume 31(1); Jan 2025

"Most viewed" articles are from the articles published during the last six months

Review
1735
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clin Mol Hepatol. 2023;29(Suppl):S17-S31.   Published online November 29, 2022
View: 20557   Download: 1,361  Web of Science: 141  Crossref: 155
Original Article
1814
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo
Clin Mol Hepatol. 2023;29(3):721-732.   Published online March 22, 2023
View: 22649   Download: 1,613  Web of Science: 261  Crossref: 272
Review
1748
Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
Clin Mol Hepatol. 2023;29(Suppl):S32-S42.   Published online December 14, 2022
View: 15959   Download: 589  Web of Science: 194  Crossref: 225
Snapshot
1901
Examining the therapeutic landscape of beta-blockers in portal hypertension
Anna Brujats, Càndid Villanueva
Clin Mol Hepatol. 2024;30(4):1055-1059.   Published online March 6, 2024
View: 5948   Download: 65
Original Article
1984
Gut microbiome and metabolome signatures in liver cirrhosis-related complications
Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk
Clin Mol Hepatol. 2024;30(4):845-862.   Published online July 25, 2024
View: 4293   Download: 961  Web of Science: 2  Crossref: 4
Review
1896
Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis
Jiaorong Qu, Le Wang, Yufei Li, Xiaojiaoyang Li
Clin Mol Hepatol. 2024;30(3):303-325.   Published online February 28, 2024
View: 5011   Download: 309  Web of Science: 5  Crossref: 7
Original Article
1918
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George
Clin Mol Hepatol. 2024;30(3):436-448.   Published online April 16, 2024
View: 4898   Download: 282  Web of Science: 9  Crossref: 11
Review
1714
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin
Clin Mol Hepatol. 2023;29(1):77-98.   Published online October 13, 2022
View: 12902   Download: 753  Web of Science: 70  Crossref: 76
Original Article
1917
Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li
Clin Mol Hepatol. 2024;30(3):449-467.   Published online April 16, 2024
View: 4514   Download: 393  Web of Science: 5  Crossref: 7
1905
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim
Clin Mol Hepatol. 2024;30(3):360-374.   Published online March 15, 2024
View: 4453   Download: 331  Web of Science: 3  Crossref: 3
Review
1955
Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury
Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li
Clin Mol Hepatol. 2024;30(4):585-619.   Published online July 1, 2024
View: 2856   Download: 292  Web of Science: 1  Crossref: 1
Snapshot
1874
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen
Clin Mol Hepatol. 2024;30(3):582-584.   Published online December 29, 2023
View: 8235   Download: 96
Review
Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol. 2023;29(suppl):S5-S16.   Published online December 28, 2022
View: 9647   Download: 567  Web of Science: 74  Crossref: 79
Original Article
1904
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2024;30(3):345-359.   Published online March 12, 2024
View: 4256   Download: 408  Web of Science: 6  Crossref: 6
1928
Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu
Clin Mol Hepatol. 2024;30(3):515-538.   Published online May 10, 2024
View: 3710   Download: 277  Web of Science: 2  Crossref: 2
Special Issue
2011
KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol. 2024;30(Suppl):S5-S105.   Published online August 19, 2024
View: 2303   Download: 186  Web of Science: 3  Crossref: 5
Original Article
1940
Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting
Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du
Clin Mol Hepatol. 2024;30(4):735-755.   Published online May 29, 2024
View: 2848   Download: 302  Crossref: 2
Review
1755
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao
Clin Mol Hepatol. 2023;29(2):206-216.   Published online December 22, 2022
View: 8659   Download: 508  Web of Science: 54  Crossref: 47
Original Article
1926
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol. 2024;30(3):487-499.   Published online May 7, 2024
View: 3364   Download: 249  Web of Science: 1  Crossref: 2
1975
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Clin Mol Hepatol. 2024;30(4):807-823.   Published online July 23, 2024
View: 2555   Download: 272  Web of Science: 1  Crossref: 2
1881
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2024;30(2):235-246.   Published online January 26, 2024
View: 5983   Download: 284  Web of Science: 18  Crossref: 20
1991
Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis
Hee Yeon Kim, Jung Hwan Yu, Young Eun Chon, Seung Up Kim, Mi Na Kim, Ji Won Han, Han Ah Lee, Young-Joo Jin, Jihyun An, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol. 2024;30(Suppl):S199-S213.   Published online July 30, 2024
View: 2323   Download: 129  Web of Science: 1  Crossref: 1
Review
1967
Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
Clin Mol Hepatol. 2024;30(4):620-648.   Published online July 11, 2024
View: 2563   Download: 246  Web of Science: 4  Crossref: 4
Editorial
The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clin Mol Hepatol. 2023;29(2):355-357.   Published online March 9, 2023
View: 6035   Download: 131  Web of Science: 45  Crossref: 48
Review
1807
Acute-on-chronic liver failure: Terminology, mechanisms and management
Vinay Kumar BR, Shiv Kumar Sarin
Clin Mol Hepatol. 2023;29(3):670-689.   Published online March 20, 2023
View: 8074   Download: 819  Web of Science: 17  Crossref: 21
Original Article
1942
Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho
Clin Mol Hepatol. 2024;30(3):561-576.   Published online June 3, 2024
View: 3158   Download: 144  Web of Science: 2  Crossref: 4
1992
KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression
Young Hoon Jung, Yun Ji Lee, Tam Dao, Kyung Hee Jung, Junjie Yu, Ah-Reum Oh, Yelin Jeong, HyunJoon Gi, Young Un Kim, Dongryeol Ryu, Michele Carrer, Utpal B. Pajvani, Sang Bae Lee, Soon-Sun Hong, KyeongJin Kim
Clin Mol Hepatol. 2024;30(4):895-913.   Published online August 5, 2024
View: 2153   Download: 281
Review
1842
Recent advances in the management of hepatocellular carcinoma
Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang
Clin Mol Hepatol. 2024;30(1):1-15.   Published online July 21, 2023
View: 8241   Download: 413  Web of Science: 22  Crossref: 24
Original Article
1913
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma
Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
Clin Mol Hepatol. 2024;30(3):406-420.   Published online April 11, 2024
View: 3487   Download: 185  Web of Science: 4  Crossref: 4
Review
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(3):326-344.   Published online April 26, 2024
View: 3113   Download: 162  Web of Science: 4  Crossref: 2

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS
FOLLOW US
Twitter
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 5622
TOTAL : 2380294
Close layer